Numark Max Strength Sinus Relief With Decongestant (Phenylephrine Hydrochloride, Paracetamol, Caffeine Citrate)

Phenylephrine hydrochloride, the active ingredient in Numark Max Strength Sinus Relief With Decongestant, is a nasal decongestant presented as an oral tablet for oral use. It is combined with paracetamol and caffeine citrate to relieve sinus pressure, headache and fever in adults.

GNH USA supplies Numark Max Strength Sinus Relief With Decongestant as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Numark Max Strength Sinus Relief With Decongestant acts on the upper‑respiratory symptom complex to provide multi‑symptom relief. - Common cold: reduces nasal congestion, headache and mild fever. - Acute sinusitis: alleviates sinus pressure and facial pain. - Influenza‑like illness: provides analgesia and antipyretic effect while easing breathing.

Common Side Effects: - Nasal dryness or irritation - Headache - Nausea or upset stomach - Insomnia or restlessness - Dizziness - Tremor

Serious or Rare Side Effects: - Hypertension or marked increase in blood pressure - Cardiac arrhythmia - Severe allergic reaction (anaphylaxis) - Elevated liver enzymes or hepatic injury - Seizures (rare)

Before using this product, consider the following precautions. - Pregnancy: consult a healthcare professional before use. - Breastfeeding: use with caution and under medical advice. - Cardiovascular disease: avoid if you have uncontrolled hypertension. - Liver impairment: monitor paracetamol intake and avoid excess alcohol. - Drug interactions: review all concomitant medications with a pharmacist. - Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Phenylephrine, paracetamol and caffeine may interact with several medicines. Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other sympathomimetic agents (e.g., pseudoephedrine): may cause excessive vasoconstriction. - Certain antihypertensive drugs: may reduce their effectiveness. Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (e.g., fluoroquinolones): increase caffeine levels. - CYP2E1 inducers (e.g., chronic alcohol use): alter paracetamol metabolism. - Diuretics: may enhance phenylephrine‑induced blood pressure rise. - Anticoagulants with high‑dose paracetamol: monitor bleeding risk. - Alcohol: increases risk of liver toxicity.